EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 01 April

A healthy pipeline: will new innovations deliver for patients?

What comes to mind when we think of the biggest unmet needs in modern medicine? Is it infectious diseases and inflammatory disorders? Or cancers and Alzheimer’s disease? Or perhaps it’s the thousands of rare diseases that collectively affect millions of Europeans?

The new EFPIA Pipeline Review reveals that these disease areas are among the top priorities of researchers running clinical trials today to investigate new medicines and vaccines.   

The comprehensive report found that in 2020 alone, around 5,000 clinical trials were launched – despite the disruption caused by the COVID-19 pandemic. In fact, the volume of trials has increased over the past five years. Read more

Watch our video here:

News

EFPIA statement in response to the Council compromise agreement on the Commission Proposal...
26 March 2021

Unfortunately, we regret that the Member States’ compromise risks creating a more inefficient system Read more

EFPIA – Vaccines Europe response to global leaders urgent call for international pandemic treaty...
30 March 2021

The devastating human and economic cost of the COVID-19 pandemic has underlined the need for a global response. Read more

Events

Health Innovation: No Citizen left behind
07 April 2021 (Virtual Event)

Online conference organised by APIFARMA and EFPIA Read more

Launch Event: Joint letter on COVID-19 and cancer
07 April 2021 (Virtual Event)

More than 200 cancer stakeholder organisations globally endorsed the campaign Joint letter on COVID-19 and cancer Read more

We published

IQVIA/EFPIA Pipeline Review 2021
26 March 2021 (Publications)

This document contains a pipeline overview, deep dives of the eight areas, as well as considerations for innovation... Read more

What we are reading

Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope
On 30 March 2021 (pharmaphorum)

Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir... Read more

How much value do innovative medicines generate for the economy?
On 29 March 2021 (The Irish Times)

Pandemic has prompted re-evaluation of healthcare systems and funding models, writes Bernard Mallee director of communications... Read more

Covid : « La levée des brevets sur les vaccins ne réglerait pas le défi de la production de...
On 27 March 2021 (Le Monde)

Une tribune au « Monde », Frédéric Collet, le président des Entreprises du médicament Read more

Latvia: Striving to Catch Up to its Neighbours on Innovation Access
On 23 March 2021 (PharmaBoardroom)

Dr Valters Bolevics, director general of the Association of International Research-based Pharmaceuticals Manufacturers... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu